Bayer, J&J's Xarelto scripts stagnate as discounts, competition pile up

As Bristol-Myers Squibb and Pfizer's superstar Eliquis continues to gobble up share in the warfarin alternative market, Bayer and Johnson & Johnson’s rival anticoagulant Xarelto is showing less-than-stellar prescription results.